The JADA® System for treatment of abnormal postpartum uterine bleeding, and the team behind the product, join Laborie, strengthening the company's commitment to improving maternal health. Joining an ...
The Organon board of directors has approved the deal. The transaction is expected to close in the first quarter of 2026, subject to required regulatory approvals. “I am incredibly proud of the work ...
The American Hospital Association is partnering with Epic on the Safer Births Postpartum Hemorrhage Collaborative, a ...
It’s Black Maternal Health Week. Here’s everything you should know to protect yourself and those you love. As a board-certified obstetrician and gynecologist, Kameelah Phillips, MD, knows what it ...
Net proceeds will be applied to debt reduction, advancing Organon’s ongoing deleveraging efforts Positions Organon for future investment in growth opportunities with a focus on women’s health ...
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global women’s health company, today announced clearance by the U.S. Food and Drug Administration (FDA) of the Special 510(k) for ...
The JADA ® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. Organon (NYSE: OGN) is a global ...
Please provide your email address to receive an email when new articles are posted on . Two postpartum hemorrhage-control devices resulted in similar rates of blood loss, transfusion and device ...
Current estimates of postpartum hemorrhage prevalence often rely on subjective visual estimation of blood loss for diagnosis, which might underestimate the burden of this complication. In a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results